 Kevin Bielamowicz
Concepts (154)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Neoplasms | 11 | 2025 | 302 | 1.790 |
Why?
| | Medulloblastoma | 4 | 2022 | 18 | 1.120 |
Why?
| | T-Lymphocytes | 8 | 2025 | 318 | 1.120 |
Why?
| | Glioma | 2 | 2025 | 83 | 1.080 |
Why?
| | Glioblastoma | 6 | 2018 | 89 | 1.060 |
Why?
| | Central Nervous System Neoplasms | 2 | 2025 | 69 | 1.030 |
Why?
| | Proto-Oncogene Proteins c-met | 1 | 2025 | 23 | 0.940 |
Why?
| | Neoplasm Recurrence, Local | 4 | 2025 | 639 | 0.880 |
Why?
| | RNA-Binding Protein EWS | 1 | 2024 | 13 | 0.860 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 1 | 2024 | 20 | 0.850 |
Why?
| | Interleukin-13 Receptor alpha2 Subunit | 3 | 2018 | 4 | 0.840 |
Why?
| | Protein Kinase Inhibitors | 1 | 2025 | 231 | 0.810 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2025 | 336 | 0.790 |
Why?
| | Craniospinal Irradiation | 2 | 2021 | 9 | 0.780 |
Why?
| | Receptor, erbB-2 | 4 | 2025 | 79 | 0.760 |
Why?
| | Receptors, Antigen, T-Cell | 4 | 2018 | 48 | 0.750 |
Why?
| | Hypothyroidism | 2 | 2021 | 56 | 0.730 |
Why?
| | Protons | 2 | 2021 | 74 | 0.610 |
Why?
| | Antigenic Variation | 2 | 2018 | 3 | 0.610 |
Why?
| | Receptor, EphA2 | 1 | 2018 | 6 | 0.570 |
Why?
| | Immunotherapy, Adoptive | 4 | 2025 | 156 | 0.410 |
Why?
| | Cerebellar Neoplasms | 3 | 2022 | 22 | 0.410 |
Why?
| | Neoplasms | 4 | 2025 | 1314 | 0.410 |
Why?
| | Child, Preschool | 9 | 2025 | 4046 | 0.400 |
Why?
| | Neuroblastoma | 2 | 2024 | 50 | 0.400 |
Why?
| | Cancer Vaccines | 3 | 2021 | 78 | 0.350 |
Why?
| | Child | 15 | 2025 | 7194 | 0.350 |
Why?
| | Testicular Hydrocele | 1 | 2010 | 3 | 0.330 |
Why?
| | Thrombocytopenia | 1 | 2011 | 93 | 0.330 |
Why?
| | Genital Diseases, Female | 1 | 2010 | 18 | 0.330 |
Why?
| | Hernia, Inguinal | 1 | 2010 | 20 | 0.330 |
Why?
| | Vagina | 1 | 2010 | 46 | 0.320 |
Why?
| | Humans | 28 | 2025 | 52441 | 0.320 |
Why?
| | Immunotherapy | 4 | 2024 | 251 | 0.300 |
Why?
| | Infant | 4 | 2025 | 3709 | 0.280 |
Why?
| | Female | 14 | 2025 | 28277 | 0.260 |
Why?
| | Male | 12 | 2025 | 26874 | 0.260 |
Why?
| | Antineoplastic Agents | 3 | 2024 | 1216 | 0.260 |
Why?
| | para-Aminobenzoates | 1 | 2025 | 1 | 0.240 |
Why?
| | Lactams, Macrocyclic | 1 | 2025 | 19 | 0.240 |
Why?
| | Lactams | 1 | 2025 | 28 | 0.240 |
Why?
| | Aminopyridines | 1 | 2025 | 19 | 0.240 |
Why?
| | Pathology, Molecular | 1 | 2025 | 27 | 0.230 |
Why?
| | Pathology, Surgical | 1 | 2025 | 23 | 0.230 |
Why?
| | Neurofibroma, Plexiform | 1 | 2024 | 5 | 0.220 |
Why?
| | Sulfonamides | 1 | 2025 | 137 | 0.220 |
Why?
| | Benzamides | 1 | 2024 | 52 | 0.220 |
Why?
| | Molecular Targeted Therapy | 1 | 2025 | 135 | 0.220 |
Why?
| | Pyrazoles | 1 | 2025 | 116 | 0.220 |
Why?
| | Neurofibromatosis 1 | 1 | 2024 | 34 | 0.220 |
Why?
| | Rhabdoid Tumor | 1 | 2024 | 13 | 0.210 |
Why?
| | Neoplastic Syndromes, Hereditary | 1 | 2024 | 18 | 0.210 |
Why?
| | Eyelid Diseases | 1 | 2024 | 11 | 0.210 |
Why?
| | Xenograft Model Antitumor Assays | 3 | 2020 | 218 | 0.210 |
Why?
| | Histiocytosis, Langerhans-Cell | 1 | 2024 | 32 | 0.210 |
Why?
| | Gene Rearrangement | 1 | 2024 | 76 | 0.210 |
Why?
| | Tumor Cells, Cultured | 3 | 2020 | 441 | 0.200 |
Why?
| | Bacterial Infections | 1 | 2023 | 96 | 0.200 |
Why?
| | Bacteremia | 1 | 2023 | 87 | 0.190 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2025 | 1020 | 0.190 |
Why?
| | Rhabdomyosarcoma, Alveolar | 1 | 2022 | 8 | 0.190 |
Why?
| | Sarcoma, Ewing | 1 | 2022 | 31 | 0.190 |
Why?
| | Proton Therapy | 1 | 2021 | 12 | 0.180 |
Why?
| | Adrenal Insufficiency | 1 | 2021 | 19 | 0.180 |
Why?
| | Hematologic Neoplasms | 1 | 2023 | 101 | 0.180 |
Why?
| | DNA-Binding Proteins | 1 | 2024 | 423 | 0.180 |
Why?
| | Leukemia | 1 | 2021 | 67 | 0.180 |
Why?
| | Sepsis | 1 | 2023 | 236 | 0.170 |
Why?
| | Mice, SCID | 2 | 2018 | 178 | 0.170 |
Why?
| | Hypothalamic Diseases | 1 | 2020 | 1 | 0.170 |
Why?
| | Ependymoma | 1 | 2020 | 6 | 0.160 |
Why?
| | Cerebrospinal Fluid | 1 | 2020 | 30 | 0.160 |
Why?
| | Adolescent | 5 | 2025 | 6713 | 0.160 |
Why?
| | Methylphenidate | 1 | 2020 | 75 | 0.150 |
Why?
| | Mice | 5 | 2025 | 5899 | 0.150 |
Why?
| | Mice, Inbred NOD | 1 | 2018 | 91 | 0.140 |
Why?
| | Central Nervous System Stimulants | 1 | 2020 | 198 | 0.140 |
Why?
| | Weight Loss | 1 | 2020 | 257 | 0.140 |
Why?
| | Cell Proliferation | 2 | 2018 | 1013 | 0.130 |
Why?
| | Receptors, Cell Surface | 1 | 2017 | 111 | 0.130 |
Why?
| | Diagnosis, Differential | 3 | 2024 | 1028 | 0.130 |
Why?
| | Tumor Escape | 1 | 2016 | 18 | 0.130 |
Why?
| | Apoptosis | 2 | 2018 | 1120 | 0.120 |
Why?
| | Neoplasm Proteins | 1 | 2017 | 328 | 0.120 |
Why?
| | Animals | 5 | 2025 | 13485 | 0.110 |
Why?
| | Cell Nucleus | 1 | 2014 | 189 | 0.100 |
Why?
| | Retrospective Studies | 3 | 2021 | 6694 | 0.100 |
Why?
| | Up-Regulation | 1 | 2014 | 462 | 0.090 |
Why?
| | Plasma Cell Granuloma, Pulmonary | 1 | 2011 | 1 | 0.090 |
Why?
| | Septo-Optic Dysplasia | 1 | 2011 | 3 | 0.090 |
Why?
| | Moyamoya Disease | 1 | 2011 | 7 | 0.090 |
Why?
| | Obesity | 1 | 2020 | 1176 | 0.090 |
Why?
| | Slipped Capital Femoral Epiphyses | 1 | 2011 | 9 | 0.090 |
Why?
| | Lung Neoplasms | 1 | 2017 | 643 | 0.090 |
Why?
| | Tumor Microenvironment | 2 | 2024 | 257 | 0.090 |
Why?
| | Medical History Taking | 1 | 2011 | 46 | 0.090 |
Why?
| | Young Adult | 3 | 2025 | 4346 | 0.090 |
Why?
| | Lymphocyte Activation | 2 | 2025 | 161 | 0.080 |
Why?
| | Adult | 5 | 2025 | 14205 | 0.080 |
Why?
| | Antigens, Neoplasm | 2 | 2021 | 145 | 0.070 |
Why?
| | Ultrasonography | 1 | 2010 | 416 | 0.070 |
Why?
| | Prognosis | 3 | 2020 | 2100 | 0.070 |
Why?
| | Cell Line, Tumor | 2 | 2025 | 1429 | 0.070 |
Why?
| | Pyrrolidines | 1 | 2025 | 65 | 0.060 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2025 | 46 | 0.060 |
Why?
| | MutS Homolog 2 Protein | 1 | 2024 | 12 | 0.050 |
Why?
| | DNA Mismatch Repair | 1 | 2024 | 18 | 0.050 |
Why?
| | CTLA-4 Antigen | 1 | 2024 | 32 | 0.050 |
Why?
| | Follow-Up Studies | 2 | 2020 | 2294 | 0.050 |
Why?
| | Survival Rate | 2 | 2017 | 944 | 0.050 |
Why?
| | Fever | 1 | 2023 | 112 | 0.050 |
Why?
| | Maximum Tolerated Dose | 1 | 2022 | 39 | 0.050 |
Why?
| | Glucocorticoids | 1 | 2024 | 234 | 0.050 |
Why?
| | Biopsy | 1 | 2024 | 594 | 0.050 |
Why?
| | Longitudinal Studies | 1 | 2024 | 756 | 0.040 |
Why?
| | Growth Hormone | 1 | 2021 | 96 | 0.040 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2022 | 230 | 0.040 |
Why?
| | Radiotherapy Dosage | 1 | 2021 | 256 | 0.040 |
Why?
| | Incidence | 1 | 2024 | 1096 | 0.040 |
Why?
| | Colorectal Neoplasms | 1 | 2024 | 286 | 0.040 |
Why?
| | Injections, Intraventricular | 1 | 2020 | 13 | 0.040 |
Why?
| | HEK293 Cells | 1 | 2020 | 236 | 0.040 |
Why?
| | Neoplasm Metastasis | 1 | 2020 | 235 | 0.040 |
Why?
| | Cross-Sectional Studies | 1 | 2024 | 1677 | 0.040 |
Why?
| | Quality of Life | 1 | 2024 | 893 | 0.040 |
Why?
| | Drug Delivery Systems | 1 | 2020 | 148 | 0.040 |
Why?
| | Treatment Outcome | 2 | 2020 | 5508 | 0.040 |
Why?
| | Mutation | 1 | 2024 | 1331 | 0.040 |
Why?
| | Microfilament Proteins | 1 | 2017 | 44 | 0.030 |
Why?
| | Prospective Studies | 1 | 2023 | 2433 | 0.030 |
Why?
| | Anti-Bacterial Agents | 1 | 2023 | 816 | 0.030 |
Why?
| | Magnetic Resonance Imaging | 1 | 2024 | 1507 | 0.030 |
Why?
| | Aged | 2 | 2024 | 10242 | 0.030 |
Why?
| | Adenoviridae | 1 | 2017 | 46 | 0.030 |
Why?
| | Cytomegalovirus | 1 | 2017 | 32 | 0.030 |
Why?
| | Herpesvirus 4, Human | 1 | 2017 | 43 | 0.030 |
Why?
| | Interleukin-13 | 1 | 2016 | 15 | 0.030 |
Why?
| | Neoplasm Transplantation | 1 | 2016 | 86 | 0.030 |
Why?
| | Transgenes | 1 | 2016 | 55 | 0.030 |
Why?
| | Infant, Newborn | 1 | 2024 | 2871 | 0.030 |
Why?
| | Protein Multimerization | 1 | 2016 | 57 | 0.030 |
Why?
| | Middle Aged | 2 | 2024 | 13133 | 0.030 |
Why?
| | Protein Binding | 1 | 2016 | 673 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2017 | 1202 | 0.030 |
Why?
| | Adoptive Transfer | 1 | 2014 | 30 | 0.030 |
Why?
| | Cell Cycle | 1 | 2014 | 236 | 0.020 |
Why?
| | Recurrence | 1 | 2014 | 680 | 0.020 |
Why?
| | Groin | 1 | 2011 | 16 | 0.020 |
Why?
| | Cough | 1 | 2011 | 55 | 0.020 |
Why?
| | Hypoglycemia | 1 | 2011 | 62 | 0.020 |
Why?
| | Penis | 1 | 2011 | 85 | 0.020 |
Why?
| | Radiography | 1 | 2011 | 469 | 0.020 |
Why?
| | Anemia, Sickle Cell | 1 | 2011 | 101 | 0.020 |
Why?
| | Pain | 1 | 2011 | 373 | 0.020 |
Why?
|
|
Bielamowicz's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|